# US 2001/0055771 A1 · Exploiting genomics in the search for new drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055771 A1
- Document ID: US20010055771A1
- Status: Published application
- Kind: A1
- Application number: 09/900,845
- Filed: 2001-07-06
- Published: 2001-12-27
- Earliest claimed: 1998-12-18
- Assignees: Affymetrix, Inc.
- Inventors: David J. Lockhart; Lisa Wodicka; Ming Hsiu Ho
- Web page: https://patentgrep.com/patent/US20010055771A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The cellular effects of potentially therapeutic compounds are characterized in mammalian cells and yeast. In the latter case the effects can be characterized on a genome-wide scale by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrays.

## Claims

### Claim 1

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to both compound 52 and flavopiridol.

### Claim 2

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to both compound 52 and flavopiridol.

### Claim 3

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to compound 52 but not to flavopiridol.

### Claim 4

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to compound 52 but not to flavopiridol.

### Claim 5

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in response to flavopiridol but not to compound 52.

### Claim 6

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in response to flavopiridol but not to compound 52.

### Claim 7 (depends on 1)

The set of claim 1 wherein the gene is also down-regulated in cdc28-4 mutants.

### Claim 8 (depends on 2)

The set of claim 2 wherein the gene is also up-regulated in cdc28-4 mutants.

### Claim 9 (depends on 1)

The set of claim 1 wherein the gene is up-regulated in cdc28-4 mutants.

### Claim 10 (depends on 2)

The set of claim 2 wherein the gene is down-regulated in cdc28-4 mutants.

### Claim 11

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated in cdc28-4 mutants.

### Claim 12

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is down-regulated or up-regulated in response to both compound 52 and flavopiridol.

### Claim 13

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated or down-regulated in cdc28-4 mutants.

### Claim 14 (depends on 13)

The set of claim 13 wherein the up-regulation or down-regulation is at least two fold as compared to wild-type.

### Claim 15

A set of at least two probes, wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated in cdc28-4 mutants.

### Claim 16 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is not up-regulated or down-regulated in response to compound 52 or flavopiridol.

### Claim 17 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is not up-regulated or down-regulated in response to compound 52.

### Claim 18 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is not up-regulated or down-regulated in response to flavopiridol.

### Claim 19 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated or down-regulated in response to compound 52.

### Claim 20 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated or down-regulated in response to flavopiridol.

### Claim 21 (depends on 13)

The set of claim 13 wherein each of said probes comprises a segment of the nucleotide sequence of a gene which is up-regulated or down-regulated in response to both flavopiridol and compound 52.

### Claim 22

The set of any of the preceding claims wherein the genes are yeast genes.

### Claim 23 (depends on 22)

The set of claim 22 wherein the yeast is Saccharomyces cerevesiae.

### Claim 24

The set of any of the preceding claims wherein the genes are human genes.

### Claim 25

The set of any of the preceding claims wherein the probes are immobilized on a solid support.

### Claim 26

The set of any of the preceding claims wherein the probes are immobilized on an array.

### Claim 27

The set of any of the preceding claims wherein up-regulation or down-regulation is determined by a difference of at least three-fold from a control.

### Claim 28

The set of any of the preceding claims which comprises at least 3, probes.

### Claim 29

The set of any of the preceding claims which comprises at least 5 probes.

### Claim 30

The set of any of the preceding claims which comprises at least 7 probes.

### Claim 31

The set of any of the preceding claims which comprises at least 9 probes.

### Claim 32

The set of any of the preceding claims which comprises at least 11 probes.

### Claim 33

The set of any of the preceding claims which comprises at least 20 probes.

### Claim 34

The set of any of the preceding claims which comprises at least 30 probes.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The set of any of claims 1-31 which consists of less than 10 probes.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The set of any of claims 1-32 which comprises less than 20 probes.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The set of any of claims 1-33 which consists of less than 30 probes.

### Claim 38

The set of any of the preceding claims which consists of less than 100 probes.

### Claim 39

The set of any of the preceding claims which consists of less than 1000 probes.

### Claim 40

The set of any of the preceding claims which comprises less than 10000 probes.

### Claim 41 (depends on 25)

The set of claim 25 wherein at least 10% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 42 (depends on 25)

The set of claim 25 wherein at least 20% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 43 (depends on 25)

The set of claim 25 wherein at least 40% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 44 (depends on 25)

The set of claim 25 wherein at least 60% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 45 (depends on 25)

The set of claim 25 wherein at least 80% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 46 (depends on 25)

The set of claim 25 wherein at least 90% of probes on the solid support comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 47 (depends on 26)

The set of claim 26 wherein at least 10% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 48 (depends on 26)

The set of claim 26 wherein at least 20% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 49 (depends on 26)

The set of claim 26 wherein at least 40% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 50 (depends on 26)

The set of claim 26 wherein at least 60% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 51 (depends on 26)

The set of claim 26 wherein at least 80% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 52 (depends on 26)

The set of claim 26 wherein at least 90% of probes on the array comprise segments of genes whose regulation is affected by compound 52, flavopiridol, or cdc28-4.

### Claim 53

A method of comparing the specificity of drugs, comprising:
contacting a first drug with a first population of cells and a second drug with a second population of said cells;
preparing a transcription indicator from each of the first and the second populations of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
preparing a transcription indicator from a third population of said cells which is not contacted with a drug;
hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes induced by the first and the second drugs;
comparing changes induced by the first and second drugs, wherein a drug which effects more changes is less specific than a drug which effects fewer changes.

### Claim 54 (depends on 53)

The method of claim 53 wherein the first drug is flavopiridol.

### Claim 55 (depends on 53)

The method of claim 53 wherein the first drug is compound 52.

### Claim 56 (depends on 53)

The method of claim 53 wherein the cells are yeast cells.

### Claim 57 (depends on 53)

The method of claim 53 wherein the first and second drugs affect a common target protein.

### Claim 58 (depends on 53)

The method of claim 53 wherein the cells are mammalian cells.

### Claim 59 (depends on 53)

The method of claim 53 wherein the array comprises at least 1000 oligonucleotides of distinct sequence.

### Claim 60 (depends on 53)

The method of claim 53 wherein the array comprises at least 6000 oligonucleotides of distinct sequence.

### Claim 61 (depends on 53)

The method of claim 53 wherein the first drug has a known beneficial effect and the second drug is identified as useful if it induces a similar pattern of changes.

### Claim 62 (depends on 53)

The method of claim 53 wherein the drug is a kinase inhibitor.

### Claim 63

A method of comparing the effects of a drug to the effects of a mutation, comprising:
contacting a drug with a first population of cells;
preparing a transcription indicator from the first population of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
preparing a transcription indicator from a second population of cells which population is not contacted with a drug, wherein the second population of cells carry a mutation in a gene of interest relative to the first population of cells;
preparing a transcription indicator from a third population of cells which is not contacted with a drug and which does not carry the mutation;
hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes caused by the drug and the mutation;
comparing the changes caused by the drug to those caused by the mutation; wherein a drug and a mutation which affect hybridization to one or more common oligonucleotides identifies the gene of interest as a candidate target of the drug; wherein a drug which affects hybridization to both common oligonucleotides and unique oligonucleotides identifies the drug as affecting targets other than the gene.

### Claim 64 (depends on 63)

The method of claim 63 wherein the drug is flavopiridol.

### Claim 65 (depends on 63)

The method of claim 63 wherein the drug is compound 52.

### Claim 66 (depends on 63)

The method of claim 63 wherein the mutation is in a kinase.

### Claim 67 (depends on 63)

The method of claim 63 wherein the mutaion is in the CDC28 gene.

### Claim 68 (depends on 63)

The method of claim 63 wherein the cells are yeast cells.

### Claim 69 (depends on 63)

The method of claim 63 wherein the cells are mammalian cells.

### Claim 70 (depends on 63)

The method of claim 63 wherein the array comprises at least 1000 oligonucleotides of distinct sequence.

### Claim 71 (depends on 63)

The method of claim 63 wherein the array comprises at least 6000 oligonucleotides of distinct sequence.

### Claim 72

A method of comparing the specificity of drugs, comprising:
comparing changes in expression induced by a first drug to those induced by a second drug, wherein a drug which effects more changes is less specific than a drug which effects fewer changes, wherein the changes are determined the process of:
contacting the first drug with a first population of cells and the second drug with a second population of said cells;
preparing a transcription indicator from each of the first and the second populations of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
preparing a transcription indicator from a third population of said cells which is not contacted with a drug;
hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells; and
comparing a first and a second populations' patterns of hybridization to a third population's pattern of hybridization to identify changes induced by the first and the second drugs.

### Claim 73 (depends on 72)

The method of claim 72 wherein the drug is flavopiridol.

### Claim 74 (depends on 72)

The method of claim 72 wherein the drug is compound 52.

### Claim 75

A method of comparing the effects of a drug to the effects of a mutation, comprising:
comparing changes in expression caused by a drug to those caused by a mutation, wherein the changes in expression are determined by the process of:
contacting the drug with a first population of cells;
preparing a transcription indicator from the first population of cells, wherein a transcription indicator is selected from the group consisting of cellular RNA, cellular mRNA, cRNA and cDNA;
preparing a transcription indicator from a second population of cells which population is not contacted with a drug, wherein the second population of cells carry the mutation in a gene of interest relative to the first population of cells;
preparing a transcription indicator from a third population of cells which is not contacted with a drug and which does not carry the mutation;
hybridizing the transcription indicators to oligonucleotide arrays to form a pattern of hybridization for each of said populations of cells;
comparing each of the first and the second populations' patterns of hybridization to the third population's pattern of hybridization to identify changes caused by the drug and the mutation;
wherein a drug and a mutation which affect hybridization to one or more common oligonucleotides identifies the gene of interest as a candidate target of the drug; wherein a drug which affects hybridization to both common oligonucleotides and unique oligonucleotides identifies the drug as affecting targets other than the gene.

### Claim 76 (depends on 75)

The method of claim 75 wherein the drug is flavopiridol.

### Claim 77 (depends on 75)

The method of claim 75 wherein the drug is compound 52.

### Claim 78 (depends on 75)

The method of claim 75 wherein the mutation is in a kinase.

### Claim 79 (depends on 75)

The method of claim 75 wherein the mutaion is in the CDC28 gene.
